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1. Introduction 
Atopic eczema/dermatitis syndrome (AEDS) is a chronic inflammatory skin disease, very 
common in childhood (1). The prevalence of AEDS is estimated to 15–30% in children and 
2–10% in adults while the incidence has shown a 2- to 3-fold increase in the past 3 decades 
in developed countries (2). This results in a significant socio-economic impact, that in the 
United States was estimated in a range from $364 million to $3.8 billion US dollars per 
year, usually considering only the direct but not the indirect costs (3). The disease is 
sustained by a complex interaction between genetic and environmental factors and is 
characterized by a skin barrier dysfunction resulting in epidermal damage and altered 
permeability to allergens and microbes (4). Depending on the association or not to IgE 
sensitization, AEDS may be defined as atopic or nonatopic. The two forms are clinically 
similar but show some differences regarding the histology, the kind of cells involved, and 
the cytokine pattern (5). 
2. Pathophysiology of AEDS 
The pathophysiologic mechanisms leading to AEDS originate from an initial skin defect at 
epidermal level, above all in the stratum corneum, which is the first of the four epidermal 
layers. The stratum corneum (from the Latin words for horned layer) is composed of large, 
flat cells containing keratin, a protein that helps keep the skin hydrated by preventing water 
evaporation, and surrounded by lamellae sheets rich in hydrophobic lipids, including 
ceramides, sphyngosynes and free fatty acids. Keratin is produced by the keratinocytes of 
the basal layer, which also keep the Langerhans cells and the intradermal lymphocytes in 
position with the epidermis. They also work to modulate the immune response by secreting 
cytokines such as TGF-beta and alpha, and a number of interleukins (6). A major advance in 
the understanding of epidermal barrier dysfunction which occurs in AEDS was the 
identification of the fundamental role of filaggrin (7). Filaggrin, which derives from the 
highly phosphorylated polypeptide profilaggrin, the main constituent of the keratohyalin 
substance in the granular layer, is a structural protein associated to filaments which are 
bound to keratin fibres in epidermal cells. Recent studies found that loss-of-function 
mutations in the gene encoding filaggrin, particularly the R501X and 2282de14 mutation, are 
associated with the development of atopic dermatitis (8-10).  
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The alteration of the epidermal structure due to filaggrin mutation induces a significant 
reduction of the lipidic component, particularly of ceramide levels (11) that leads to the well 
known phenomenon of trans-epidermal water loss (TEWL) resulting in dry skin and itching, 
while the impaired skin barrier associated with filaggrin deficiency favours the penetration 
of foreign noxae, especially allergens and microbes (12).  
Concerning allergens, it is conceivable that their facilitated access favours the 
sensitization process, especially for house dust mites, the protease activity of their major 
allergen being a further enhancing factor (13). Once entered, allergens are captured by 
dendritic cells (14) that activate an initially local Th2 but a later Th1 response along with a 
systemic Th2 response inducing the Ig isotype switching to IgE synthesis and the 
involvement of eosinophils (2). In this kind of response an important factor seems to be 
thymic stromal lymphopoietin (TSLP), an IL-7-like cytokine expressed by barrier 
epithelial cells able to activate myeloid-derived dendritic cells, macrophages and mast 
cells (15). The ongoing inflammatory process is then sustained by the Th2-related cytokine 
such as IL-5, IL-13, TNF-alpha, IL-17, and IL-31, the latter being primarily expressed in 
skin-homing Th2 cells (16). An important clinical aspect of the allergen-caused AEDS is 
the frequent evolution of manifestations to respiratory symptoms such as asthma and 
rhinitis. This process has been defined as the “atopic march” (17). Also in this case, 
filaggrin null mutation were found to be associated with the development of asthma (18). 
However, more than one model of atopic march was reported, because in a significant 
number of children asthma precedes AEDS as the onset manifestation of the atopic 
disease (19). Of note, in subjects with AEDS and no filaggrin gene mutations, the 
cytokines IL-4 and IL-13 (typical of the Th2 profile) are able to inhibit the expression of 
filaggrin (20). This suggests that if filaggrin deficiency predisposes to atopy, atopy is also 
likely to impair the filaggrin-dependent skin barrier. 
Regarding microbes, the normal skin defence is based on integrity of stratum corneum and 
on immune response by neutrophils and macrophages by production of substances which 
kill the microbes and by phagocytosis. Numerous antimicrobial peptides produced by 
keratinocytes and belonging to the classes of beta-defensins and cathelicidins are able to 
disrupt or penetrate the microbe membrane thus protecting the skin from infections (21). 
It has been demonstrated that in patients with AEDS there is a deficiency in the 
expression of beta-defensins and cathelicidins that may account for the susceptibility to 
skin infection, especially from Staphilococcus aureus (22). S. Aureus has a major role in 
AEDS, as indicated by the following features: 1) a very high density of colony-forming 
units S. aureus per cm2 of inflamed atopic skin lesions (23); 2) the higher affinity for S. 
aureus of the atopic skin compared with nonatopic or psoriatic skin (24); 3) the reduction 
of S. aureus counts on atopic skin sites following effective topical treatment (25). In any 
form of AEDS, an additional pathophysiologic role is played by the cytokine IL-31 
produced by keratinocytes, which exerts a potent pruritogenic effect (26). In fact, pruritus 
is associated with skin lesions caused by scratching or excessive washing and to 
consequent damage of keratinocytes and release of mediators, but also of autoantigens, 
and generation of autoantibodies (27). Moreover, autoreactivity phenomena also concur to 
pathogenesis of AEDS. In particular, manganese superoxide dismutase (MnSOD) of both 
human and foreign origin – especially from the long known Malassezia spp yeast (28) – 
may act as autoallergen. Specific IgE against human MnSOD correlating with the disease 
activity were detected in patients with AEDS, suggesting that human MnSOD with 
molecular mimicry with MnSOD from Malassezia may play a role, as showed by its 
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capacity to induce in vitro T-cell reactivity and eczematous skin lesions, as an 
autoallergen in subjects with both atopic and nonatopic forms (29). 
3. The allergy tests in diagnosis of AEDS 
When food allergens are the cause of AEDS, the commonly used allergy tests, such as skin 
prick tests and in vitro measurement of specific IgE antibodies, have a role in the 
diagnostic work-up (30). Concerning food-specific IgE measurement, an useful 
application was suggested by Sampson and Ho, who identified in a group of 196 children 
and adolescents with AEDS the food-specific IgE levels predicting a positive result of a 
double-blind, placebo-controlled food challenge. Such levels, showing a positive 
predictive value higher than 95%, corresponded to 6 kU/L for egg, 32 kU/L for milk, 15 
kU/L for peanut, and 20 kU/L for fish (31). The same author later confirmed the utility of 
specific IgE concentrations in predicting symptomatic allergy also for other foods such as 
wheat and soy (32). However, the advances in the knowledge of pathophysiology of 
AEDS, and particularly the understanding that in this disease the mechanisms of delayed 
hypersensitivity prevail, suggested the need of new diagnostic tools. The atopy patch test 
(APT) was recently defined as an important tool in diagnosis of AEDS, because it seems to 
have a greater significance than skin prick test or RAST, which simply detect the presence 
of specific IgE antibodies. Thus, allergy tests assessing only the immediate IgE-mediated 
phase of the allergic response can only partially detect the operating mechanisms. Instead, 
there is notable evidence supporting the capacity of the APT to reproduce the 
pathophysiologic events of AEDS. 
In biopsy-based studies, a Th2 cytokine pattern was found 24 hours after APT, but a shift to 
a Th1 pattern, as occurs in chronic AEDS skin lesions, was noted after 48 hours (33, 34). A 
more frequent positivity to APT was reported in patients with allergen-specific lymphocyte 
proliferation and expression of activation markers on peripheral blood T-cells following in 
vitro stimulation with house dust mite, cat or grass pollen allergens, than in patients without 
lymphocyte proliferation (35). Application of the APT to skin of subjects with AEDS was 
followed by an influx of inflammatory dendritic epidermal cells (36). A significant increase 
of TEWL was reported in the site of the APT application, both after 48 and 72 hours, 
compared with the control skin site (37). By immunohistochemical analysis, the presence of 
IgE on Langerhans cells was demonstrated in positive APT reactions to Dermatophagoides in 
patients with mite-associated AEDS (38). 
Clinically, patients with a diagnosis of intrinsic AEDS because of negative IgE tests 
actually had a positive APT for dust mites (39). This aspect is of particular interest, 
because AEDS patients with negative SPT and IgE measurement in serum should be 
defined as nonatopic unless APT is performed. A number of studies evaluated how 
common such patients are, with different observations. In one study the rate of positive 
APT in nonatopic patients was 23% (40), while in another study comparing AEDS patients 
with extrinsic and intrinsic forms, the rate of positive APT was 47.4% and 66.6%, 
respectively (41). In a European multicenter study, which included 314 patients with 
AEDS, the frequency of clear-cut positive APT reactions ranged from 39% with dust mites 
to 9% with celery. A notable observation from the study was that positive APT in face of 
all SPT and sIgE testing negative was found in 7% of the patients, whereas a positive APT 
without SPT or sIgE for the respective allergen was seen in 17% of the patients (42). This 
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lead the authors to conclude that, as no gold standard for aeroallergen provocation in 
AEDS exists, the relevance of aeroallergens for AEDS may be evaluated by APT in 
addition to SPT and sIgE. Moreover, in children with respiratory symptoms an exclusive 
positivity to APT with dust mites was observed (43). On the other hand, it was reported 
that in 63 children with mite-induced asthma and rhinitis, all with positive SPT and sIgE 
in serum, 16 (25%) were positive to mite APT too, indicating that delayed hypersensitivity 
reactions were involved (44). 
These observations lead us to investigate the possible factors underlying the positive 
result of APT in subjects with respiratory symptoms. In our first study, conducted on 297 
children (45), we could demonstrate that in patients with asthma or rhinitis a positive 
APT to dust mite was strongly associated with the presence of current or past AEDS. 
Instead, most subjects with respiratory disease but a negative history for AEDS had a 
positive SPT. Multivariate analysis showed that there was a high probability of a positive 
APT result in patients with AEDS (odds ratio 17.4), in patients with AEDS and respiratory 
disease (odds ratio 21.9), and in patients with past AEDS and respiratory disease (odds 
ratio 22.8). These observations were confirmed in a study on a large population of 465 
children aged 0.4 to 17.6 years. They were divided into four groups: group A, current 
AEDS (40 patients); group B, current AEDS with respiratory symptoms (156 patients); 
group C, past AEDS with respiratory symptoms (203 patients); and the control group, 
respiratory symptoms with no history of AEDS (66 patients). The APT was significantly 
more frequently positive in groups with current AEDS (groups A and B) or past AEDS 
(group C) than in the control group, while SPT and RAST were significantly more 
frequently positive in the control group (46). Such significant differences in response to 
APT in patients with diverse clinical expressions suggest that distinctive immunologic 
mechanisms lie beneath the different manifestations of hypersensitivity to dust mites. It 
seems conceivable that in subjects with a negative history for AEDS sensitization occurs 
by respiratory route and leads to the development of a Th2 pattern of response with 
ongoing production of specific IgE and consequent positive SPT and in vitro IgE tests. By 
contrast, in the case mite allergens enter through the skin, as it occurs in exposure to 
common indoor concentrations of the major allergen Der p 1 (47), such entering being 
facilitated by its proteolytic activity and in the presence of a filaggrin-dependent skin 
barrier dysfunction, a different chain of events is likely to take place. This is ultimately 
revealed by positive APT and negative SPT and in vitro IgE tests. 
The recent observations on the diagnostic significance of APT in patients with different 
clinical expressions of the disease highlighted the importance of delayed hypersensitivity in 
AEDS. This brings into question the role of simple IgE sensitization in AEDS and also the 
appropriateness of the term atopic when applied to AEDS. In fact, current evidence shows 
that up to two thirds of patients with AEDS are not atopic, therefore even to continue using 
the term atopic dermatitis is to be considered problematic (48, 49). In fact, the definition of 
atopy as “a personal or familial tendency to produce IgE antibodies in response to low doses 
of allergens” (50) seems not to be appropriate for AEDS, as many patients show a positive 
result to APT but not to IgE tests. At the same time, the definition atopy patch test seems 
unfounded, because the test does not reveal atopy, i.e. a type I hypersensitivity, but a type 
IV hypersensitivity according to Gell and Coombs classification (51). A unifying solution 
should be the use, in both cases, of the term allergy, which is defined as “a hypersensitivity 
www.intechopen.com
 Atopic Dermatitis: From Pathophysiology to Diagnostic Approach 
 
165 
reaction initiated by immunologic mechanisms” (50) and includes all known mechanisms, 
as a replacement for atopy.  
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